This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
About the trial
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowany rak prostaty z przerzutami w innych częściach ciała
- •Przerzuty w narządach lub co najmniej 4 przerzuty w kościach (zarejestrowane tomografią lub badaniem kości)
- •Bardzo niski poziom testosteronu we krwi (wynik leczenia)
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Możliwe wcześniejsze leczenie radurem lub chemioterapią (jeśli skończyło się ponad rok temu)
✗ Disqualifies
- •Wcześniejsze leczenie nowymi lekami hamującymi receptor androgenowy (enzalutamid, darolutamid, apalutamid lub abirateron) przy zaawansowanym rakzie
- •Tylko biochemiczny powrót choroby bez potwierdzenia przerzutów w badaniach obrazowych
- •Brak przerzutów widocznych w tomografii lub badaniu kości
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (66)
University of California San Diego - Moores Cancer Center
La Jolla, United States
Saint Johns Cancer Institute
Santa Monica, United States
Rocky Mountain Cancer Centers
Denver, United States
Yale Cancer Center
New Haven, United States
Advanced Urology Ins Daytona Beach
Daytona Beach, United States
Emory University School of Medicine-Winship Cancer Institute
Atlanta, United States
Associated Urological Specialists
Chicago Ridge, United States
Mass General Hospital
Boston, United States
Michigan Institute of Urology
West Bloomfield, United States
XCancer Omaha LLC
Omaha, United States
Perlmutter Cancer Centre
New York, United States
Associated Med Professionals of NY
Syracuse, United States
Montefiore Medical Center
The Bronx, United States
MidLantic Urology
Bala-Cynwyd, United States
Fox Chase Cancer Center
Philadelphia, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Tennessee Oncology
Nashville, United States
Urology San Antonio
San Antonio, United States
Inova Schar Cancer Institute
Fairfax, United States
Virginia Oncology Associates
Norfolk, United States
Fred Hutch Cancer Research
Seattle, United States
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Clayton, Australia
Novartis Investigative Site
Fortaleza, Brazil
Novartis Investigative Site
Porto Alegre, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Vancouver, Canada
Novartis Investigative Site
Halifax, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Quint-Fonsegrives, France
Novartis Investigative Site
Suresnes, France
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Nürtingen, Germany
Novartis Investigative Site
Asti, Italy
Novartis Investigative Site
Padova, Italy
Novartis Investigative Site
Trento, Italy
Novartis Investigative Site
Orbassano, Italy
Novartis Investigative Site
Verona, Italy
Novartis Investigative Site
Zwolle, Netherlands
Novartis Investigative Site
Dordrecht, Netherlands
Novartis Investigative Site
Hoofddorp, Netherlands
Novartis Investigative Site
Schiedam, Netherlands
Novartis Investigative Site
Kielce, Poland
Novartis Investigative Site
Oświęcim, Poland
Novartis Investigative Site
Skorzewo, Poland
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Santander, Spain
Novartis Investigative Site
Badajoz, Spain
Novartis Investigative Site
Lugo, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Córdoba, Spain
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Tainan, Taiwan
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.